Clinical Trial of BI 425809 Effect on Cognition and Functional Capacity in Schizophrenia
Status:
Completed
Trial end date:
2020-01-29
Target enrollment:
Participant gender:
Summary
The objective of the study is to investigate the efficacy, safety and pharmacokinetics of
four different doses of BI 425809 once daily compared to placebo given for 12 weeks in
patients with schizophrenia on stable antipsychotic treatment.